Mutant EGFR inhibitor - CAS 1421373-62-7
Catalog number: 1421373-62-7
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C27H30ClN7O2
Molecular Weight:
520.03
COA:
Inquire
Targets:
EGFR
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Synonyms:
Mutant EGFR inhibitor
MSDS:
Inquire
1.EGFR-tyrosine kinase inhibitor treatment in a patient with advanced non-small cell lung cancer and concurrent exon 19 and 21 EGFR mutations: A case report and review of the literature.
Yang Y1, Zhang B2, Li R1, Liu B1, Wang L1. Oncol Lett. 2016 May;11(5):3546-3550. Epub 2016 Apr 5.
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are considered to be effective treatments for advanced non-small cell lung cancer (NSCLC) patients with sensitizing EGFR mutations, including exon 19 deletion and exon 21 L858R mutations. However, with the development of EGFR mutation detection assays, patients with complex EGFR mutations are emerging, and their response to EGFR-TKIs remains unclear. The present study reports a case of a 62-year-old, non-smoking female patient with advanced NSCLC, presenting with concurrent EGFR 19+21 sensitizing mutations, who had a poor response to the first-line EGFR-TKI erlotinib and succumbed 5 months subsequent to diagnosis. Furthermore, the present study performed a literature review, and 18 patients with complex EGFR 19+21 mutations that had received EGFR-TKIs were identified. The majority of these patients responded well to EGFR-TKIs. To the best of our knowledge, the present case is the first to report a patient with lung adenocarcinoma with complex EGFR 19+21 sensitizing mutations that had a poor clinical response to a first-line EGFR-TKI.
2.The Frequency of EGFR Mutation in Lung Adenocarcinoma and the Efficacy of Tyrosine Kinase Inhibitor Therapy in a Hungarian Cohort of Patients.
Sárosi V1, Balikó Z1, Smuk G2, László T2, Szabó M1, Ruzsics I1, Mezősi E3. Pathol Oncol Res. 2016 Apr 22. [Epub ahead of print]
In the last decades new therapeutic drugs have been developed for the treatment of non-small cell lung cancer (NSCLC) patients. Tyrosine kinase inhibitors (TKIs) significantly increase the progression free survival (PFS) of patients with NSCLC carrying epidermal growth factor receptor (EGFR) mutations. This type of lung cancer occurs mainly among non-smoking women and Asian origin. However, the new ESMO guideline recommends EGFR mutation analysis in every patient with NSCLC, because in patients with activating EGFR mutation, TKIs should be considered as first line therapy. In our recent work, we analyzed data of patients with EGFR-mutant adenocarcinoma from January 2009. The number of patients investigated was 446, among them 44 cases were positive for EGFR mutation. The ratio of positive cases was 9.86 % that is lower than the average mutation rate in Europe and much lower than that found in Asia. The exon 19 deletion was detected in 61.
3.Discovery of 5-(methylthio)pyrimidine derivatives as L858R/T790M mutant selective epidermal growth factor receptor (EGFR) inhibitors.
Xiao Q1, Qu R2, Gao D1, Yan Q1, Tong L2, Zhang W1, Ding J2, Xie H3, Li Y4. Bioorg Med Chem. 2016 Apr 19. pii: S0968-0896(16)30273-5. doi: 10.1016/j.bmc.2016.04.032. [Epub ahead of print]
To overcome the drug-resistance of first generation EGFR inhibitors and the nonselective toxicities of second generation inhibitors among NSCLC patients, a series of 5-(methylthio)pyrimidine derivatives were discovered as novel EGFR inhibitors, which harbored not only potent enzymatic and antiproliferative activities against EGFRL858R/T790M mutants, but good selectivity over wide-type form of the receptor. This goal was achieved by employing structure-based drug design and traditional optimization strategies, based on WZ4002 and CO1686. These derivatives inhibited the enzymatic activity of EGFRL858R/T790M mutants with IC50 values in subnanomolar ranges, while exhibiting hundreds of fold less potency on EGFRWT. These compounds also strongly inhibited the proliferation of H1975 non-small cell lung cancer cells bearing EGFRL858R/T790M, while being significantly less toxic to A431 human epithelial carcinoma cells with overexpressed EGFRWT. The EGFR kinase inhibitory and antiproliferative activities were further validated by Western blot analysis for activation of EGFR and the downstream signaling in cancer cells.
4.Pretreatment neutrophil-lymphocyte ratio is not a significant prognostic factor in epidermal growth factor receptor-mutant non-small cell lung cancer patients treated with tyrosine kinase inhibitors.
Sim SH1, Beom SH1, Ahn YO2, Keam B3, Kim TM3, Lee SH3, Kim DW3, Heo DS3. Thorac Cancer. 2016 Mar;7(2):161-6. doi: 10.1111/1759-7714.12304. Epub 2015 Aug 28.
BACKGROUND: The neutrophil-lymphocyte ratio (NLR) is a marker of poor prognosis in lung cancer patients. However, previous data have been based on an heterogeneous population of lung cancer patients and various treatments. In this study, we evaluate the prognostic value of NLR in an homogeneous population of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) patients.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related EGFR Products


CAS 133550-41-1 AG 556

AG 556
(CAS: 133550-41-1)

AG 556, a dihydroxyphen derivative, has been found to be a EGFR kinase inhibitor that could probably be effective in the study of myocardial infarct and hemodyn...

CAS 698387-09-6 Neratinib

Neratinib
(CAS: 698387-09-6)

Neratinib, also known as HKI-272 or PB272, is an orally available, 6,7-disubstituted-4-anilinoquinoline-3-carbonitrile irreversible inhibitor of the HER-2 recep...

CAS 481-74-3 Chrysophanol

Chrysophanol
(CAS: 481-74-3)

Chrysophanic acid (Chrysophanol) is a natural anthraquinone with anticancer activity in EGFR-overexpressing SNU-C5 human colon cancer cells. Chrysophanic acid p...

CAS 139087-53-9 AG 494

AG 494
(CAS: 139087-53-9)

AG-494 is a EGFR (epidermal growth factor receptor) kinase inhibitor with IC50 value of 0.7 μM. It is selective over ErbB2, PDGFR and insulin receptor kinase (I...

CAS 497839-62-0 AEE-788

AEE-788
(CAS: 497839-62-0)

AEE-788 is an orally bioavailable multiple-receptor tyrosine kinase inhibitor. AEE788 inhibits phosphorylation of the tyrosine kinases of epidermal growth facto...

CAS 63177-57-1 Methyl 2,5-dihydroxycinnamate

Methyl 2,5-dihydroxycinnamate
(CAS: 63177-57-1)

Methyl 2,5-dihydroxycinnamate, a stable analog of erbstatin, is a stable, potent inhibitor of EGFR kinase activity. It is described to be four-times more stable...

CGP-59326
(CAS: 173458-56-5)

CGP-59326, a pyrrolopyrimidine derivative, has been found to be an EGFR antagonist and could used in antineoplastic studies.

CAS 1557268-88-8 Avitinib maleate

Avitinib maleate
(CAS: 1557268-88-8)

Avitinib maleate, the maleate salt form of avitinib, is a pyrrolopyrimidine-based, irreversible epidermal growth factor receptor (EGFR) mutant-selective inhibit...

CAS 183319-69-9 Erlotinib hydrochloride

Erlotinib hydrochloride
(CAS: 183319-69-9)

Erlotinib HCl potently inhibits EGFR activation in intact cells including HNS human head and neck tumor cells (IC50 20nM), DiFi humancolon cancer cells andMDA M...

PF-06747775
(CAS: 1776112-90-3)

PF-06747775, a methylpurin derivative, has been found to be an epidermal growth factor receptor antagonist and could probably be effective against cell lung can...

CAS 850140-73-7 Afatinib Dimaleate

Afatinib Dimaleate
(CAS: 850140-73-7)

Afatinib Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, res...

MTX-211
(CAS: 1952236-05-3)

MTX-211 is a dual inhibitor of EGFR and PI3K, which plays important roles in the progression of KRAS mutant colorectal cancer. MTX-211 has the potential for the...

CAS 289499-45-2 Canertinib dihydrochloride

Canertinib dihydrochloride
(CAS: 289499-45-2)

Canertinib dihydrochloride is the hydrochloride salt of an orally bio-available quinazoline with potential antineoplastic and radiosensitizing activities. Caner...

Naquotinib mesylate
(CAS: 1448237-05-5)

Naquotinib is irreversible, third-generation, epidermal growth factor receptor (EGFR) inhibitor with IC50 value of 70 nM for NCI-H1650 cell growth. It can coval...

CAS 1110813-31-4 Dacomitinib

Dacomitinib
(CAS: 1110813-31-4)

Dacomitinib, aslo known as PF-299 and PF-00299804; or PF299804, is an orally bioavailable, highly selective, second-generation small-molecule inhibitor of the p...

AZ5104
(CAS: 1421373-98-9)

AZ5104, the demethylated metabolite of AZD-9291, is a potent EGFR inhibitor with IC50 of

CAS 136831-49-7 RG14620

RG14620
(CAS: 136831-49-7)

RG14620 is a non-phenolic tyrphostin-class epidermal growth factor receptor (EGFR) inhibitor (IC50= 3 μM for HER 14 colony formation, and IC50= 1 pM for HER 14 ...

EGFR-IN-2
(CAS: 1643497-70-4)

EGFR-IN-2 is a a noncovalent, irreversible, mutant-selective second generation EGFR inhibitor. It showed excellent cellular activity against both the single and...

CAS 714971-09-2 AC480

AC480
(CAS: 714971-09-2)

AC480, also known as BMS-599626, is an orally bioavailable inhibitor of the HER1, HER2 and HER4 tyrosine kinases (IC50 =22, 32 and 190 nM, respectively) with po...

CAS 183321-74-6 Erlotinib

Erlotinib
(CAS: 183321-74-6)

Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

Chemical Structure

CAS 1421373-62-7 Mutant EGFR inhibitor

Quick Inquiry

Verification code

Featured Items